Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00844649 · ClinicalTrials.gov registry record · Phase 3

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

A Phase 3 study, sponsored by Celgene.

Completed
Registry status
Phase 3
Development phase
861
Enrollment target

NCT00844649 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 861 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00844649, a Phase 3 study, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 3
Development phase
861 participants
Enrollment target

Study Summary

Phase III Metastatic Pancreatic Cancer

Interventions

  • DRUG Gemcitabine
  • DRUG Albumin-bound paclitaxel (ABI-007)

Trial Details

FieldValue
Enrollment Target 861 participants
Start Date 2009-03-01
Est. Completion 2013-04-09
Phase Phase 3

Sponsor

Celgene

308 total trials

What the Registry Record Tells You About NCT00844649

The ClinicalTrials.gov registry entry for NCT00844649 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 861 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.

NCT00844649 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00844649 about?

NCT00844649 is a clinical study titled "Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas". Phase III Metastatic Pancreatic Cancer

What is the current status of trial NCT00844649?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 861 participants. The study started on 2009-03-01. Estimated completion is 2013-04-09.

What interventions are being tested in trial NCT00844649?

The interventions under investigation include: Gemcitabine (DRUG), Albumin-bound paclitaxel (ABI-007) (DRUG).

Who is sponsoring clinical trial NCT00844649?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.